Experimental drug tested for Tough-to-Treat breast cancer
NCT ID NCT06162351
Summary
This study tested an experimental drug called PLX038 in patients with advanced triple-negative breast cancer that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and was safe. The trial was small and ended early, so results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 75248 Cedex, France
-
Institut Curie
Saint-Cloud, 92210, France
Conditions
Explore the condition pages connected to this study.